TRIUMPH-1 (80 Weeks) The pivotal TRIUMPH-1 obesity trial (2,339 adults, no diabetes), presented at ADA 2026, extended the treatment window to 80 weeks and produced the largest pivotal weight-loss readout to date: Among the 12 mg group, 45.3% lost at least 30% of their body weight and 65.3% ended the trial with a BMI below 30
Retrieved from Varughese, M
Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most effective weight loss medication yet
Transparency & Documentation We provide Certificates of Analysis along with clear communication, verified stock, and straightforward pricing for complete trust
Broader coverage for Ozempic and others to be introduced in January, Trump official says A new deal with major drugmakers, unveiled by U.S
OTROS ARTCULOS DE INTERS Semaglutida y tirzepatida Qu nos depara el futuro